AAV gene therapy, single intracerebral injection, developed

Class

AAV gene therapy, single intracerebral injection, developed specifically for Parkinson's disease patients carrying GBA1 mutations (exact transgene not disclosed in available records)

Notes

original target text: AAV gene therapy, single intracerebral injection, developed specifically for Parkinson's disease patients carrying GBA1 mutations (exact transgene not disclosed in available records)

This entry describes an adeno-associated virus (AAV) gene therapy delivered by a single injection directly into the brain, designed for a genetically defined subset of Parkinson's disease patients who carry mutations in the GBA1 gene. GBA1 encodes glucocerebrosidase (GCase), a lysosomal enzyme that breaks down glucosylceramide. Mutations reduce GCase activity, impairing the lysosome's capacity to clear cellular debris, including aggregated alpha-synuclein, the protein implicated in Parkinson's pathology. Because GBA1 mutation carriers show more rapid disease progression and a distinct biological deficit compared with other Parkinson's patients, therapies aimed specifically at this enzyme pathway represent a precision-medicine strategy rather than a broad symptomatic treatment. The general rationale for an AAV-based approach is to introduce genetic material directly into brain tissue so that neurons or supporting glial cells produce a therapeutic protein, most plausibly a functional copy of GBA1 or a related enzyme-supporting sequence, over a sustained period following a single administration. The exact transgene used here is not specified in available records, so the precise molecular strategy cannot be confirmed. Broadly, this mechanism class matters in neurodegenerative disease because it offers a way to address an underlying enzymatic deficiency at its genetic source, rather than only managing downstream symptoms.